You are here

Global Outlook on the Narcolepsy Market by Type, Product, Distribution Channel and Geography (2019-2027)

DUBLIN, March 15, 2019 /PRNewswire/ -- The "Narcolepsy Market to 2027- Global Analysis and Forecasts by Type; Distribution Channel and Geography" report has been added to ResearchAndMarkets.com's offering.

The global narcolepsy market is expected to reach US$ 4,537.9 Mn in 2027 from US$ 2,026.8 Mn in 2018. The market is estimated to grow with a CAGR of 9.5% from 2019-2027.

The growth of the narcolepsy market is primarily attributed to the rising prevalence of sleep related neurological disorders, emerging local pharmaceutical and biopharmaceutical companies, and increasing awareness regarding neurological disorders. However, side effects and risks associated with the narcolepsy medications and delayed diagnosis and misdiagnosis of the disease are likely to pose a negative impact on the market growth.

On the other hand, robust pipeline of drugs intended for the treatment of narcolepsy is likely to have a positive impact on the growth of the global narcolepsy market in the coming years. The range of sleep disorders that are treated by neurologists is wide and includes conditions such as insomnia, sleep apnea, restless legs syndrome, and narcolepsy. These disorders cause disruptions in the normal sleep-wake mechanisms causing endogenous abnormalities. Neurological sleep related disorders is an emerging problem as the population is ageing at a rapid rate.

According to the National Institute of Health (NIH), approximately 40 million Americans suffer from neurological diseases in the US, whereas additional 20 million people experience occasional sleeping problems. Sleep attacks are not limited to periods of dull or low engagement activities, but can happen during school or work hours, in the middle of a conversation, while eating, while exercising or playing sports, or even while driving. The increasing prevalence of neurological sleep disorders and narcolepsy is likely to foster the growth of market in the coming years.

In 2018, the narcolepsy with cataplexy segment held a largest market share of 65.1% of the narcolepsy market, by type. This segment is also expected to dominate the market in 2027 owing to its significant prevalence among patients suffering with narcolepsy. Episodes of cataplexy are reported to be encountered among 55-60% of patients suffering with narcolepsy. Moreover, the similar segment is anticipated to also witness the fastest growth rate of 9.7% during the forecast period, 2019 to 2027 owing to the increasing demand for drugs to treat the disease.

Global narcolepsy market, based on product was segmented into sodium oxybate, CNS stimulants and antidepressants. Sodium oxybate segment is anticipated to grow at a CAGR of 9.8% during the forecast period. Sodium oxybate is the one of the primary medication recommended by specialists to patients suffering with narcolepsy. The high cost of the branded counterparts, availability of reimbursement with certain regions as well as approval of the drug in majority of the top markets is likely to contribute to the growth and dominance of the segment. Sodium is oxybate is also expected to exhibit highest growth witnessing a robust CAGR over the forecast years.

Some of the major primary and secondary sources for narcolepsy included in the report are World Health Organization (WHO), European Medical Agency (EMA), National Health Commission (NHC), China National Drug Administration (CNDA), Food & Drug Administration (FDA), National Institute of Neurological Disorders and Strokes, International Federation of Pharmaceutical Manufacturers & Associations and others.

Topics Covered



1. Introduction


1.1 Scope of the Study


1.2 Report Guidance


1.3 Market Segmentation


1.3.1 Global Narcolepsy Market - by Type


1.3.2 Global Narcolepsy Market - by Product


1.3.3 Global Narcolepsy Market - by Distribution Channel


1.3.4 Global Narcolepsy Market - by Geography



2. Global Narcolepsy Market - Key Takeaways



3. Research Methodology


3.1.1 Coverage


3.1.2 Secondary Research


3.1.3 Primary Research



4. Global Narcolepsy Market - Market Landscape


4.1 Overview


4.2 Pest Analysis


4.2.1 North America - Pest Analysis


4.2.2 Europe- Pest Analysis


4.2.3 Asia Pacific- Pest Analysis


4.2.4 Middle East & Africa- Pest Analysis


4.2.5 South and Central America - Pest Analysis



5. Global Narcolepsy Market - Key Market Dynamics


5.1 Key Market Drivers


5.1.1 Rising Prevalence of Sleep Related Neurological Disorders


5.1.2 Emerging Local Pharmaceutical and Biopharmaceutical Companies


5.1.3 Increasing Awareness Regarding Neurological Disorders


5.2 Key Market Restraints


5.2.1 Side Effects and Risks Associated With Narcolepsy Medications


5.2.2 Delayed Diagnosis Or Misdiagnosis of Narcolepsy


5.3 Key Market Opportunities


5.3.1 Robust Pipeline Drugs For Narcolepsy


5.4 Future Trends


5.4.1 New Treatments For Narcolepsy


5.5 Impact Analysis



6. Narcolepsy Market - Global Analysis


6.1 Global Narcolepsy Market Revenue Forecasts and Analysis


6.2 Global Narcolepsy Market, by Geography - Forecasts and Analysis


6.3 Performance of Key Players


6.3.1 Jazz Pharmaceuticals Plc


6.3.2 Teva Pharmaceutical Industries Ltd.


6.4 Brand Analaysis


6.4.1 Marketed Drugs:


6.4.2 Provigil


6.4.2.1 Overview:


6.4.2.2 Drug Description:


6.4.2.3 Advantages & Disadvantages:


6.4.3 Xyrem


6.4.3.1 Overview:


6.4.3.2 Drug Description:


6.4.3.3 Advantages & Disadvantages:


6.4.4 Nuvigil


6.4.4.1 Overview:


6.4.4.2 Drug Description:


6.4.4.3 Advantages & Disadvantages:


6.5 Pipeline Analysis



7. Narcolepsy Market Analysis and Forecasts To 2027 - Type


7.1 Overview


7.2 Type Market Revenue and Forecasts Analysis (US$ Mn)


7.3 Narcolepsy With Cataplexy Market


7.3.1 Overview


7.3.2 Narcolepsy With Cataplexy Market Revenue and Forecast To 2027 (US$ Mn)


7.4 Narcolepsy Without Cataplexy Market


7.4.1 Overview


7.4.2 Narcolepsy Without Cataplexy Market Revenue and Forecast To 2027 (US$ Mn)


7.5 Secondary Narcolepsy Market


7.5.1 Overview


7.5.2 Secondary Narcolepsy Market Revenue and Forecast To 2027 (US$ Mn)



8. Narcolepsy Market Analysis and Forecasts To 2027 - Product


8.1 Overview


8.2 Product Market Revenue and Forecasts Analysis (US$ Mn)


8.3 Central Nervous System Stimulants Market


8.3.1 Overview


8.3.2 Central Nervous System Stimulants Market Revenue and Forecast To 2027 (US$ Mn)


8.4 Sodium Oxybate Market


8.4.1 Overview


8.4.2 Sodium Oxybate Market Revenue and Forecast To 2027 (US$ Mn)


8.5 Antidepressants Market


8.5.1 Overview


8.5.2 Antidepressants Market Revenue and Forecast To 2027 (US$ Mn)



9. Narcolepsy Market Analysis and Forecasts To 2027 - Distribution Channel


9.1 Overview


9.2 Distribution Channel Market Revenue and Forecasts Analysis (US$ Mn)


9.3 Hospital Pharmacies Market


9.3.1 Overview


9.3.2 Hospital Pharmacies Market Revenue and Forecast To 2027 (US$ Mn)


9.4 Retail Pharmacies Market


9.4.1 Overview


9.4.2 Retail Pharmacies Market Revenue and Forecast To 2027 (US$ Mn)



10. Narcolepsy Market Revenue and Forecasts To 2027 - Geographical Analysis


10.1 North America Narcolepsy Market


10.2 Europe Narcolepsy Market


10.3 Asia Pacific Narcolepsy Market


10.4 Middle East & Africa Narcolepsy Market


10.5 South and Central America Narcolepsy Market



11. Narcolepsy Market - Industry Landscape


11.1 Overview


11.2 Comparative Company Analysis


11.3 Growth Strategies In the Narcolepsy Market, 2015-2018


11.4 Organic Growth Strategies


11.4.1 Overview


11.4.2 Expansions


11.4.3 Product Launches


11.4.4 Other Organic Growth Strategies


11.5 Inorganic Growth Strategies


11.5.1 Overview


11.5.2 Agreements


11.5.3 Acquisitions


11.5.4 Other Inorganic Growth Strategies



12. Narcolepsy Market -Key Company Profiles


12.1 Teva Pharmaceutical Industries Ltd.


12.1.1 Key Facts


12.1.2 Business Description


12.1.3 Financial Overview


12.1.4 Product Portfolio


12.1.5 SWOT Analysis


12.1.6 Key Developments


12.2 Jazz Pharmaceuticals Plc


12.3 Arena Pharmaceuticals, Inc.


12.4 Graymark Healthcare, Inc.


12.5 Novartis Ag


12.6 Takeda Pharmaceutical Company Limited


12.7 Mylan N.V.


12.8 Bioprojet


12.9 Shionogi & Co., Ltd.


12.10 Ligand Pharmaceuticals, Inc.



For more information about this report visit

https://www.researchandmarkets.com/research/wwh77x/global_outlook_on?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-outlook-on-the-narcolepsy-market-by-type-product-distribution-channel-and-geography-2019-2027-300813183.html

SOURCE Research and Markets